Docetaxel induced-JNK2/PHD1 signaling pathway increases degradation of HIF-1α and causes cancer cell death under hypoxia

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Oh, Eun Taex ^a   Kim, Chan Woo ^a   Kim, Soo Jung ^a   Lee, Jae Seon ^a   Hong, Soon Sun ^a   Park, Heon Joo ^a  

^a Inha University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; EGLN2 PROTEIN, HUMAN; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE; MITOGEN ACTIVATED PROTEIN KINASE 9; TAXOID;

AMINO ACID SEQUENCE; CELL DEATH; CELL HYPOXIA; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UBIQUITINATION;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL DEATH; CELL HYPOXIA; CELL LINE, TUMOR; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; HYPOXIA-INDUCIBLE FACTOR-PROLINE DIOXYGENASES; MITOGEN-ACTIVATED PROTEIN KINASE 9; NEOPLASMS; PROTEOLYSIS; SIGNAL TRANSDUCTION; TAXOIDS; UBIQUITINATION;

EID: 84973304712     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep27382     Document Type: Article

References (44)

1. Alsamarai, S. et al. Pneumonitis related to docetaxel: case report and review of the literature. In vivo 23, 635-638 (2009).
2. Horwitz, S. B. Mechanism of action of taxol. TIPS 13, 134-136 (1992).
3. Schiff, P. B. & Horwitz, S. B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77, 1561-1565 (1980).
4. Yang, L. X., Wang, H. J. & Holton, R. A. In vitro efficacy of a novel chemoradiopotentiator-taxoltere metro. Int J Radiation Oncology Biol Phys 46, 159-163 (2000).
5. Choy, H., Rodriguez, F. F., Koester, S., Hilsenbeck, S. & Von Hoff, D. D. Investigation of taxol as a potential radiation sensitizer. Cancer 71, 3774-3778 (1993).
6. Gupta, N., Hu, L., Fan, P. D. & Deen, D. F. Effect of taxol and radiation on brain tumor cell lines. Proc Am Assoc Cancer Res 35, 647 (1994).
7. Milas, L., Hunter, N. R., Mason, K. A., Kurdoglu, B. & Peters, L. J. Enhancement of tumor radioresponse of a murine mammary carcinoma by paclitaxel. Cancer Res 54, 3506-3510 (1994).
8. Escuin, D., Kline, E. R. & Giannakakou, P. Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxiainducible factor-1α accumulation and activity by disrupting microtubule function. Cancer Res 65, 9021-9028 (2005).
9. Mabjeesh, N. J. et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3, 363-375 (2003).
10. 2 homeostasis. Curr Opin Genet Dev 8, 588-594 (1998).
11. 2, and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 107, 1-3 (2001).
12. Semenza, G. L. Hypoxia-inducible factor 1: control of oxygen homeostasis in health and disease. Pediatric Res 49, 614-617 (2001).
13. Liu, Y. V. et al. Rack1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitorinduced degradation of HIF-1alpha. Mol Cell 26, 207-217 (2001).
14. Liu, Y. V. & Semenza, G. L. RACK1 vs. HSP90: competition for HIF-1α degradation vs. stabilization. Cell Cycle 6, 656-659 (2007).
15. Semenza, G. L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3, 721-732 (2003).
16. Zhong, H. et al. Overexpression of hypoxia-inducible factor 1a in common human cancers and their metastases. Cancer Res 59, 5830-5835 (1999).
17. Ema, M. et al. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1 alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA 94, 4273-4278 (1997).
18. Gu, Y. Z., Moran, S. M., Hogenesch, J. B., Wartman, L. & Bradfield, C. A. Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expr 7, 205-213 (1998).
19. Luo, W. et al. Hsp70 CHIP selectively mediate ubiquitination and degradation of hypoxia-inducible factor (HIF)-1 but not HIF-2. J Biochem Chem 285, 3652-3663 (2010).
20. Trisciuoglio, D. et al. Bcl-2 regulates HIF-1alpha protein stabilization in hypoxic melanoma cells via the molecular chaperone HSP90. PLoS One 5, e11772 (2010).
21. 2 tension. Proc Natl Acad Sci USA 92, 5510-5514 (1995).
22. 2 sensing. Science 292, 464-468 (2001).
23. 2-regulated prolyl hydroxylation. Science 292, 468-472 (2001).
24. Masson, N., Willam, C., Maxwell, P. H., Pugh, C. W. & Ratcliffe, P. J. Independent function of two destruction domains in hypoxiainducible factor-a chains activated by prolyl hydroxylation. EMBO J 20, 5197-5206 (2001).
25. Bruick, R. K. & McKnight, S. L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294, 1337-1340 (2001).
26. Maxwell, P. H. & Ratcliffe, P. J. Oxygen sensors and angiogenesis. Semin Cell Dev Biol 13, 29-37 (2002).
27. Ehrlich, E. S. et al. Regulation of Hsp90 client proteins by a Cullin5-RING E3 ubiquitin ligase. Proc Natl Acad Sci USA 106, 20330-20335 (2009).
28. Zhang, D., Li, J., Costa, M., Gao, J. & Huang, C. JNK1 mediates degradation HIF-1α by a VHL independent mechanism that involves the chaperones Hsp90/Hsp70. Cancer Res 70, 813-823 (2010).
29. Lee, S. H. et al. Runx2 protein stabilizes hypoxia-inducible factor-1α through competition with von Hippel-Lindau protein (pVHL) and stimulates angiogenesis in growth plate hypertrophic chondrocytes. J Biol Chem 287, 14760-14771 (2012).
30. Gao, W. et al. Hypoxia-induced expression HIF-1alpha and its target genes in umbilical venous endothelial cells of Tibetans and immigrant han. Comp Biochem Physiol C Toxicol Pharmacol 141, 93-100 (2005).
31. Kim, T. H. et al. NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1α. Cancer Res 71, 2260-2275 (2012).
32. Taniguchi, T. et al. Involvement of NK-kappaB and mitochondrial pathways in docetaxel-induced apoptosis of human oral squamous cell carcinoma. Int J Mol Med 15, 667-673 (2005).
33. Xu, L., Pathak, P. S. & Fukumura, D. Hypoxia-induced activation of p38 mitogen-activated protein kinase and phosphatidylinositol 3′ -kinase signaling pathways contributes to expression of interleukin 8 in human ovarian carcinoma cells. Cancer Res 10, 701-707 (2004).
34. 2+/CaM in the activation of MAPK and p38 gamma. Adv Exp Med Biol 475, 293-302 (2000).
35. Gonzal, E. et al. Hypoxia induces selective SAPK/JNK-2-AP-1 pathway activation in the nucleus tractus solitarii of the conscious rat. J Neurocheom 73, 665-674 (1999).
36. Wang, T. et al. Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways. J Biol Chem. 273, 4928-4936 (1998).
37. Flamant, L., Notte, A., Ninane, N., Raes, M. & Michiels, C. Anti-apoptotic role of HIF-1 and AP-1 in paclitaxel exposed breast cancer cells under hypoxia. Mol Cancer 9, 191 (2010).
38. Notte, A. et al. Taxol-induced unfolded protein response activation in breast cancer cells exposed to hypoxia: ATF4 activation regulates autophagy and inhibits apoptosis. Int J Biochem Cell Biol. 62, 1-14 (2015).
39. Notte, A., Ninane, N., Arnould, T. & Michiels, C. Hypoxia counteracts taxol-induced apoptosis in MDA-MB-231 breast cancer cells: role of autophagy and JNK activation. Cell Death Dis. 16, e638 (2013).
40. Sato, S. et al. Activity of docetaxel in paclitaxel-resistant ovarian cancer cells. Cancer Chemother Pharmacol 53, 247-252 (2004).
41. Ortmann, B. et al. CDK-dependent phosphorylation of PHD1 on serine 130 alters its substrate preference in cell. J Cell Sci 129, 191-205 (2016).
42. Li, X. Y. et al. Expression, purification and characterization of human PHD1 in Escherichia coli. J Biochem 144, 555-561 (2008).
43. Zhao, J., Du, F., Shen, G., Zheng, F. & Xu, B. The role of hypoxia-inducible factor-2 in digestive system cancers. Cell Death Dis. 6, e1600 (2015).
44. Oh, E. T. et al. Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells. Invest New Drugs 30, 435-442 (2012).